Automatic Point-of-Care System Measures COVID-19 Antibodies Along with HbA1c, CRP, U-Albumin within 3 Minutes

A new automatic point-of-care system measures COVID-19 antibodies along with HbA1c, glycated albumin, hemoglobin, C-reactive protein and U-Albumin within just three minutes.

DxGen Corp. (Korea) has launched the Epithod AutoDx analyzer and Epithod SARS-CoV-2 qAb antibody test kit, which allows to easily test IgM/IgG antibodies to SARS-CoV-2. The Epithod SARS-CoV-2 qAb is a vitro diagnostic (IVD) test that can detect IgM and IgG antibodies produced after virus infection in human whole blood and serum/plasma. According to DxGen, the Epithod SARS-CoV-2 qAb test kit has a sensitivity and specificity of 97% and 100%, respectively at 95% confidence intervals.


The test kit is a gold nanoparticle-based immunoassay for semi-quantitative determination with the easy-to-use Epithod AutoDx analyzer. Users can put the test kit and specimen on the tray and press a button, after which the analyzer perform the entire test process automatically. A key benefit of the Epithod AutoDx analyzer is that in addition to measuring IgM/IgG antibodies to SARS-CoV-2, it can also measure various underlying diseases test markers such as HbA1c, glycated albumin, hemoglobin, C-reactive protein, U-Albumin, etc. By providing medical professionals with various and valuable diagnostic information, the Epithod system can be effectively used not only for COVID-19 diagnosis tests, but also for complication diagnosis tests and patient prognosis monitoring and treatment in various medical front lines.

"We are currently processing the FDA EUA, and we have plan to quickly add test kits such as D-dimer, COVID-19 Antigen, Influenza A/B, etc.," said Dr. Jinwoo Lee, CEO of DxGen Corp.